News

The milestone was triggered by Genentech’s filing of an investigational new drug application with the FDA for an antibody-drug conjugate (ADC) utilizing Seattle Genetics’s technology. Under the terms

Fareed Kureshy, president and CEO of AutoGenomics, said: “This patent is the result of our collaboration with Dr Erik Thunnissen, a prominent clinician and opinion leader in the

Mr Taylor succeeds Roger Gale, who has resigned as president and CEO after completing a two-year term of employment. Mr Gale remains the chairman of Calypte’s board of

Vitrolife’s product Steen Solution is part of a new method for functional testing and preservation of lungs outside the body. The technology makes it possible for the first

Bryan Warwood, vice president of operations at BioSurface, said: “The Mbec assay fills an important customer need in biofilm research for a high throughput screening system. BioSurface Technologies

The letter marks notable progress towards gaining approval and does not require Eurand to conduct additional clinical trials prior to approving EUR-1008. In addition, the FDA recently completed

The acquisition will provide Ortho-Clinical Diagnostics, a Johnson & Johnson company, with access to a high performance technology platform – currently in development in this rapidly growing area

The purchase price for the assets is $11 million subject to adjustment for changes in working capital to be determined subsequent to the closing date. Eamonn Hobbs, president

Bolton Medical’s NBS or non bare stent is a thoracic stent-graft with a proximal end configuration consisting of a sinusoidal nitinol stent covered with fabric. It gives surgeons